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Neuroleptics also known as major tranquillizers and 
antipsychotics - are among the most commonly prescribed types 
of medication in use today. While in psychiatric practice, 
they are used extensively in the treatment of psychotic 
disorders, they are also widely employed in general medical 
practice as anti emetics and as sedatives in the treatment of 
the acute brain syndromes that arise from certain organic 
disorders. 
In the treatment of the psychoses, such as schizophrenia and 
major affective disorder, these agents are effective in the 
control of psychotic phenomena over a period of time. Their 
antipsychotic effect is attributed to their ability to block 
post-synaptic dopamine receptors in the various dopamine 
pathways in the brain. In addition, blockade of post synaptic 
dopamine receptors in the mesolimbic system may account for 
their ability to ameliorate the hyperdopaminergic state 
postulated as the underlying neurochemical dysfunction in 
schizophrenia. The same action in the nigrostriatal pathway 
may account for unwanted extra pyramidal effects that result 
from prolonged administration. 












neurobiology and brain microstructure, 
explosion of scientific data in 
neurosciences. 
evident in the recent 
the field of the 
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Due to the non-specificity of many of the commonly prescribed 
neuroleptic agents, unwanted side 
various 
effects may arise due to 
their action on neurotransmitter systems. 
Occasionally a rare, but potentially life-threatening disorder 
may arise following neuroleptic exposure, which has been 
termed the neuroleptic malignant syndrome. 
THE NEUROLEPTIC MALIGNANT SYNDROME [NHS] 
The Neuroleptic malignant syndrome has been ascribed to an 
idiosyncratic reaction to neuroleptic drug therapy and may 
have a fatal outcome. The characteristic clinical features 




altered state of 
dysfunction which 
manifests as diaphoresis, tachycardia, tachypnoea and labile 
blood pressure. These features are associated with laboratory 
findings of a leukocytosis, a raised serum creatine 
phosphokinase and a low serum iron concentration. 
The first description of the neuroleptic malignant syndrome 
was by French psychiatrists, Delay et al. in 1960. The paper 
appeared in the proceedings of the Societe Medico-
Psychologique for December 21, 1959, in a communication on the 
use of the then new drug Haloperidol and was described as a 
neurovegetative complication. The first description in 
English was by Delay and Deniker (1968), who used the term as 
a subheading in a chapter on drug-induced extrapyramidal 
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symptoms in the "Handbook of Clinical Neurology" (Eds. P.J. 
Winken & G.W. Bruyn, 1968). 
In the English medical literature the first reference to Delay 
and Deniker's description of the syndrome was by Metzler 
(1973), who recognized it as a complication of treatment with 
depot fluphenazine enanthate and only four papers mentioned 
the term before 1980. Following Caroff's article in the North 
American literature entitled the "Neuroleptic Malignant 
syndrome" (1980), it has gained increasing recognition. 
CHAPTER ONE 
LITERATURE REVIEW 
Diagnostic and Conceptual Issues 
The NMS was first thought to be a variant of drug fever in 
which hyperpyrexia, autonomic and other neurological 














diagnostic criteria into major and minor manifestations to aid 
clinicians in the recognition of the syndrome. 
Minor Manifestations 
Tachycardia 









In his view, a positive diagnosis could only be made if the 
patient satisfied all the major criteria plus two of the minor 
criteria. 
Other writers have favoured a spectrum concept of NMS. Fogel & 
Goldberg (1985), considered that NMS was a severe neuroleptic 
related neurotoxicity with various combinations of 
extrapyramidal, cortical and autonomic dysfunction. Guze & 
Baxter (1985a), in their review of NMS, supported this 
concept. Whereas Cohen et al. (1985), suggested that the NMS 
may be an exaggerated form of neuroleptic induced 
parkinsonism, Conlon ( 1986), argued that NMS represented an . 
extreme end of the spectrum of neuroleptic related toxic 
reactions. In their review article, Shalev and Munitz (1986), 
reported on so-called formes fruste, or atypical cases of the 
NMS, i.e. forms without fever or muscular rigidity. 
On the other hand, Adityanjee (1988), challenged the validity 
of the spectrum concept of the disorder which had been based 
on anecdotal reports using arbitrary criteria for diagnosis. 
He claimed that the spectrum concept of NMS was an artefact of 
arbitrary definition and stated that NMS could not be 
diag~osed in the absence of any one of four ascribed clinical 
components, viz. muscular rigidity, an altered state of 
consciousness, hyperpyrexia [over 39°c] and autonomic 
dysfunction (tachycardia >90/min, respiratory rate >25/min, BP 
fluctuation of at least 20mm Hg in systolic pressure, 
excessive sweating and incontinence) . Elevation of CPK and 
leukocytosis were considered as supportive features only, as 
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they are non-specific abnormalities which are associated with 
a number of other medical conditions. 
In his often cited review, Caroff ( 1980), described NMS as 
having an abrupt, fulminant onset extending over 24 to 72 
hours, whereas others have described a more insidious 
evolution of the symptoms (Bernstein, 1979; Chayasirisabhon, 
1983; Coons, 1982; Ewert, 1983; Feibel, 1981). 
INCIDENCE 
It is inevitable that with the lack of consistency in defining 
the criteria for diagnosis, estimations of incidence have 
differed widely. 
In an early review of NMS, caroff (1980), estimated the 
incidence as 0.5 - 1.0% of all treatment episodes. Similar low 
figures were given by Shalev and Munitz (1986), who estimated 
incidence was o. 4%. From a prospective assessment of 679 
patients, Pope, Keck et al. (1986), quoted an incidence of 
1. 4% for neuroleptic treated patients. A high incidence of 
2.4% was cited by Addonizio (1986), from a retrospective chart 
analysis of 82 consecutive in-patients. Gelenberg et al. 
(1988), studied 2173 patients prospectively and identified 
only one patient who developed NMS out of 1470 given 
neuroleptics. The estimated incidence in this study was only 
O. 07%. In their prospective study of 9733 Chinese patients 
treated with neuroleptics Deng et al. (1990), found an 
incidence of 0.12%. 
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In a recent North American study, Keck et al. (1991), noted a 
significant decline in the frequency of the syndrome. In their 
study of 2695 neuroleptic treated patients, · the frequency of 
occurrence of the syndrome was only 0.15% as compared to 1.4% 
in their earlier study. They suggested that the decline may 
be due to an increased awareness of risk factors and early 
intervention. 
NMS AND ASSOCIATED FACTORS 
Pharmacological agents: 
Numerous reports have cited the most frequently used 
neuroleptics, the phenothiazines and butyrophenones as usually 
causing the NMS. However, all neuroleptics, including newer 
generation agents, have been implicated. These include 
sulpiride, clozapine, zuclopenthixol decanoate and 
metaclopramide. NMS has also been associated with the use of 
drugs which alter dopaminergic function. Toru et al. (1987) 
and Fuji take et al. ( 1984), reported cases of NMS following 
the abrupt cessation of dopamine agonists which were used to 
treat parkinsonism. 
being precipitated 
The syndrome has also been recorded as 
by several other drugs or drug 
combinations, which lower dopamine receptor activity. For 
example, Ritchie (1983), reported a case following an overdose 
of dothiepin and phenelzine. Eiser et al. (1982), described a 
case involving amitriptyline and thioridazine in therapeutic 
doses. NMS has also been associated with other pharmacologic 
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agents such as amoxapine ( a new tricyclic antidepressant) , 
carbamazepine, and lithium alone (Susman & Addonizio, 1987) or 
in combination with other medication. 
NMS and Organic Brain Syndrome 
Some reports have described NMS as occurring in various 
organic states treated with neuroleptic agents. These include 
Hunt i ngton's chorea (Burke et al. 1981), Alzheimer's disease 
( Addoni zio, 1987; Finucane et al. 1988) , mental retardation 
and AIDS (Breitbart et al. 1988). 
NMS and Psychiatric Disorder 
The NMS 
patients 
has been described 
with psychotic 
as occurring predominantly in 
disorders. Controversy exists 
concerning the association of NMS with schizophrenia or the 
affective disorders. In a recent prospective analysis of 24 
cases of the NMS, Rosebush & Stewart ( 1989) , noted a higher 
preponderance of affective disorder and a low incidence of 
schizophrenia in the cases presenting with NMS. Only one of 
the 20 patients in this study had a diagnosis of schizophrenia 
and that case also presented with an affective component to 
the schizophrenic disorder. 
Addonizio ( 1986), also found a higher incidence of NMS in 
patients with a diagnosis of affective disorder. Of the 10 
patients with diagnosed NMS, in this retrospective survey of 
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82 consecutive in-patients, seven had an affective disorder, 
one patient had a schizoaffective diagnosis and two patients 
were diagnosed as having schizophrenia. In view of these 
findings, both Rosebush and Addonizio have suggested that 
affective disorder may be a risk factor in the development of 
the NMS. 
Sporadic cases reported in t he literature also suggest an 
association of NMS with affective states, mainly bipolar 
affective disorder and manic states (Goekoop & Carbaat, 1982; 
Singh, 1981; Smith & Carter, 1984; Spring & Frankel, 1981; 
Town, 1982), but also depressive states (Sumiyashi et al. 
1983). 
It is interesting to note that there are cases where NMS has 
allegedly occurred in non-psychotic patients, for example, in 
patients with psychopathy, acute grief reaction and heroin 
addiction (Kellam, 1987). Two cases were reported as occurr i ng 
in fit patients given neuroleptics as pre-operative medication 
(Konikoff et al. 1984; Moyes, 1973). 
THE RELATIONSHIP OF NMS TO CATATONIA 
Lethal catatonia ("Todliche katatonie"), a term coined by 
Stauder (1934), was used to describe a life threatening 
febrile neuropsychiatric disorder, which was widely reported 
before the introduction of modern psychopharmacologic agents. 
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• 
Symptoms of unexplained fulminating hyperpyrexia, widely 
described in the course of catatonia, have been described 
since the beginning of the nineteenth century, especially in 
the French literature as "delire aigue". Bell first described 
the syndrome in English as "Bell's mania" (Bell, 1849). 
There has been a notable decline in the reporting of catatonia 
in the post neuroleptic era, al though occasional cases have 
been described in the European and Asian literature. Mann 
(1986), in his review of lethal catatonia, identified 292 
cases reported since 1960. He suggested that catatonia is a 
'syndrome' rather than a specific disease and may occur during 
the course of either an organic or functional disorder. H~ 
suggested that it is a non-specific response of the CNS 
associated with various neurological, medical and psychiatric 
syndromes, in brief, it is a syndrome with varied aetiologies. 
The clinical entity recognised as the NMS closely resembles 
advanced catatonia. Several authors have observed that the 
clinical features of the two syndromes are indistinguishable 
(Fricchione, 1983; Meltzer, 1973; Weinburger, 1977). Mann 
( 1986), identified 65 patients ( 22%) in his series of 292 
patients with catatonia where the clinical phenomenology 
appeared to be equally consistent with a diagnosis of NMS. It 
is interesting to note that these patients were diagnosed as 
lethal catatonia only after neuroleptic exposure. 
Several writers have proposed that the neuroleptic malignant 
syndrome represents a neuroleptic-induced, toxic or iatrogenic 
10 
form of lethal catatonia (Bourgeois, 1981; Fricchione, 1985; 
Gabris, 1983; Kick, 1981). 
In his overview of NMS and its relationship to catatonia, 
Fricchione (1985), presented the hypothesis that 'neuroleptic 
induced catatonia' and so-called 'psychogenic catatonia' may 
share a common pathophysiological pathway. He suggested that 
'neuroleptic induced catatonia' may be analogous to the 
potentially lethal variant known as the NMS and likewise such 
an analogous relationship can be said to exist between so 
called benign "psychogenic catatonia" which, in its more 
severe form, may become a lethal variant of catatonia. 
The clinical features of catatonia include mutism, posturing, 
stereotypy, waxy flexibility, negativism, catalepsy, 
incoherent speech, an altered state of consciousness which may 
become a profound stupor, and psychomotor agitation. These 
features may be associated with somatic disturbance such as 
tachycardia, sweating, tachypnoea, labile blood pressure and 
fever. In the lethal variant, extreme agitation may lead to 
exhaustion, dehydration and hyperthermia with coma, cardio-
vascular collapse and death. In many cases skeletal 
musculature has been described as flaccid in the terminal 
stupor whereas other cases have displayed muscular rigidity. 
Stauder (1934), noted that each of his 27 patients experienced 
a stuporous period following psychomotor agitation in which 
patients in the terminal phase of illness would lie with their 
"musculature tensed" and "bizarre posturing" which lasted two 
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to four days and ended in death. Early literature refers to 
cases of lethal catatonia in which the entire clinical course 
was characterized by stupor and rigidity unassociated with 
hyperactivity (Bell, 1849; Tolsma, 1956). 
Some authors claim that the NMS has often gone unrecognized as 
cases involving neuroleptic exposure were sometimes attributed 
to lethal catatonia (Lancet, 1984; Zubenko, 1983). The 
difficulties in distinguishing between the two syndromes have 
been cited by several writers (Caroff, 1980; Powers, 1976; 
Weinberger & Kelley, 1977). There is ongoing debate as to 
whether catatonia and NMS should be differentiated. Castillo 
et al. (1988) and Fleishhacker (1990), argued that there is a 
need to differentiate the two syndromes for the purpose of 
treatment, since patients with catatonia may require 
neuroleptics or ECT, whereas patients with NMS require the 
immediate cessation of neuroleptic medication and the 
administration of dopaminergic agents. 
Kellam (1987), in an excellent review of the NMS, suggested 
that in some cases of apparent NMS, the underlying catatonic 
state was probably overlooked as attention was focused on the 
pathogenicity of the neuroleptic agent. Kellam states as 
follows: "this raises the question as to whether catatonia may 
itself sometimes become a life threatening condition and 




The two major competing theories attempting to explain NMS are 
a central dopaminergic blockade versus a direct toxic 
( hypermetabol ic) effect on skeletal muscle. Burke et al. 
(1981), described a patient with Huntington's Chorea, who 
developed NMS while taking alpha methyl tyrosine and 
tetrabenazine; the former inhibits dopamine synthesis, while 
the latter depletes CNS catecholamines by interfering with 
their storage. They suggested that NMS is caused by dopamine 
depletion or blockade resulting in derangement of central 
thermoregulation. Henderson and Wooton (1981), supported this 
hypothesis, citing a patient with Parkinson's disease and 
chronic psychosis who developed NMS when dopaminergic agents 
Levadopa carbidopa and amantadine were withdrawn. The patient 
was also receiving lithium and haloperidol. A similar case 
was reported by Toru et al. ( 1981), where a patient with 
Parkinson's disease developed NMS when 1-dopa/carbidopa and 
amantadine were abruptly discontinued. The patient had no 
neuroleptic exposure. 
Fricchione (1985), postulated that NMS is secondary to 
dopamine blockade in the mesostriatum, which is responsible 
for the motor disorder in the preoptic anterior nuclei of 
hypothalmus accounting for hyperthermia, and in the brain stem 
which results in mutism. 
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Rosebush and Mazurek (1991), postulated that the acute phase 
reaction may have a role in NMS. In their study of 26 cases 
of NMS they noted a high occurrence ( 96%) of low serum iron 
concentration during the active phase of the illness, which 
may have had some bearing on striatal dopamine receptor 
function. 
Nisijima and Ishiglfto (1990), in their study of CSF monamine 
metabolism in eight cases of NMS, found that the levels of 
homovanillic acid (HVA) were significantly low in patients 
with NMS compared to controls in the active phase and after 
recovery. They claimed that this supported the central 
dopamine blockade theory of NMS pathophysiology. They also 
suggested that there may be decreased dopamine metabolism in 
patients susceptible to NMS. 
They also reported significantly decreased levels of 5-HIAA in 
patients with active NMS and after recovery, compared to the 
control group, suggesting a relationship between development 
of NMS and a disturbance of serotonin metabolism. The levels 
of nor adrenalin (NA) in patients with active NMS were 
significantly higher than in normal subjects, and were within 
the normal range after recovery. The levels of MHPG also 
tended to rise in patients with active NMS, compared with the 
levels during recovery. They postul~d that this finding was a 
result of increased sympathetic nervous system activity and 
may well reflect the physical stress caused by NMS. They 
commented that a similar response is also seen in other 
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conditions such as malignant hyperthermia, head injury and 
subarachnoid haemmorhage. 
Several investigators have suggested that NMS and malignant 
hyperthermia (MH) may share a common pathogenetic mechanism 
(Caroff, 1980; Levenson, 1985; Shalev & Munitz, 1986). 
Clinically, MH and NMS are similar, both presenting as 
hypermetabolic episodes, usually with pronounced muscle 
rigidity, rhabdomyolysis and hyperthermia. Laboratory evidence 
of MH-sus~eptibility in six NMS patients provided support for 
the hypothesis put forward by Caroff et al. (1987), that the 
development of muscular rigidity in NMS is a function of 
similar skeletal muscle abnormalities as might be present in 
MH susceptible patients, which may be triggered by 
neuroleptics. 
DIFFERENTIAL DIAGNOSIS 
Investigators have noted the similarity in the clinical 
features of the NMS and other disorders such as heat stroke, 
malignant hyperthermia, drug reactions such as anticholinergic 
toxicity, MAOI toxicity or hyperthermic reactions to 
synthetic narcotics or tricyclics when given together with 
MAOI ' s. An important factor to consider in differential 
diagnosis is the occurrence of a febrile medical illness in 
the course of 
(1986), observed 
neuroleptic therapy. Levinson and Simpson 
that out of 39 reported cases of NMS, 16 
patients with features of NMS also had medical of these 
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problems that occurred during the course of neuroleptic 
therapy which could have accounted for the presence of 
fever. 
Several features of NMS are seen in anticholinergic toxicity, 
i.e. fever, delirium, tachycardia and a history of 
psychotropic medication. However, anticholinergic toxicity is 
characterized by a lack of sweating rather than diaphoresis, 
and a low blood pressure versus a labile or increased BP, 
urinary retention instead of incontinence. The laboratory 
findings of leukocytosis and clinical finding of muscular 
rigidity are usually absent. 
Several writers (Levenson, 1985; Levinson (1986); Fricchione, 
1985; Rosebush, 1989) included catatonia as part of the 
differential diagnosis, and emphasized the need to 
differentiate the syndrome from the NMS. 
Patients taking neuroleptics are at increased risk of heat 
stroke which may be related to the inhibition of sweating 
secondary to anticholinergic medications. This syndrome may 
resemble NMS, particularly if there are associated 
extrapyramidal side effects. Distinguishing features are the 
absence of sweating, a low blood pressure and normal muscle 
enzymes and white cell count. 
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PREDISPOSING/RISK FACTORS FOR THE DEVELOPMENT OF THE NMS 
Innumerable patients are treated with neuroleptic and other 
psychotropic medication with no major sequelae. The factors 
predisposing a small percentage of patients to the NMS are 
unknown, but, due to the potential lethal outcome of this 
syndrome, it is vital to identify possible risk factors. 
Addonizio {1987), in his review and analysis of 115 cases of 
NMS, was unable to identify any significant factors 
contributing to the development of the NMS. He concluded that 
case reports alone would not provide an answer to the NMS but 
that controlled prospective studies might reveal the 
underlying pathophysiological mechanism. More recent studies 
have linked NMS to several possible preconditions: 
From the findings in their prospective study of 26 episodes of 
NMS, Rosebush & Stewart {1989), listed the following features 
as possible predisposing factors: 
an increasing dosage of neuroleptics or initial 
introduction to neuroleptics in a vulnerable patient. 
agitation and restlessness. 
dehydration. 
a diagnosis of affective disorder. 
concurrent use of medication such as lithium or 
antidepressants. 
other forms of organic brain pathology. 
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Keck and Pope (1989), found significant differences between a 
group of patients with NMS and a group of neuroleptic-treated 
controls. Based on these findings, they suggested the 
following as possible risk factors for the NMS: 
psychomotor agitation, 
rapid neuroleptisation, 
an affective disorder. 
Harsh (1987), identified dehydration as a possible risk factor 
in a study of nine patients with NMS. It is interesting to 
note that Levinson and Simpson (1986), in their retrospective 
survey of 39 patients with extrapyramidal side effects and 
fever noted that 24 patients were agitated prior to the onset 
of symptoms and that dehydration was present in 12 of them. 
In their study of Japanese patients, Itoh et al. (1977), 
commented on the incidence of agitation before NMS. 
Otani et al. (1991), suggested that the predisposition to NMS 
may be genetically transmitted, based on a study of a Japanese 
family where a mother and her two daughters all experienced 
NMS on therapeutic dosage of neuroleptics. 
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SPECIAL INVESTIGATIONS 
Investigative findings are usually non-specific and are useful 
in excluding or confirming the clinical diagnosis of NMS. The 
laboratory findings commonly associated with NMS are: 
raised serum creatine phosphakinase 
leukocytosis 
low serum iron concentration. 
The iso enzyme phosphocreatine kinase (CPK mm) level is often 
elevated and may exceed 30,000 I.U./L reflecting myonecrosis. 
Rhabdomyolys i s with associated myoglobinuria may lead to acute 
renal failure in severe cases of NMS. The transaminases, 
lactic dehydrogenase and alkaline phosphatase may also be 
raised. There is uncertainty as to whether these enzymes are 
from liver or muscle. 
The role of serum iron, CPK and leukocytosis in NMS will be 
discussed further in chapter three. 
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MANAGEMENT OF THE NMS 
Pharmacological Intervention 
Dantrolene/Bromocriptine: 
Although various treatments have been proposed, most 
clinicians adhere to basic principles such as the immediate 
cessation of neuroleptic therapy and supportive treatment. 
There are conflicting accounts in the literature as to the 
efficacy of pharmacological intervention with dopamine 
agonists such as Bromocriptine and/ or skeletal muscle 
relaxants such as dantrolene. Levenson ( 1985) , found that 
cases of NMS treated with supportive measures only, did not 
differ in course of illness from those who had received 
bromocriptine and/or dantrolene. 
Rosebush and Stewart (1991) analyzed 55 cases and found that 
patients treated with bromocriptine and/or dantrolene had 
signs of NMS for a mean of 9.9 days compared with 6-8 days in 
those receiving supportive care only. However, they could not 
exclude the possibility that the drug treated patients may 
have been more seriously ill than those treated with 
supportive measures only. Deng et al. (1991), found 
bromocriptine and dantrolene of little use in their patients. 
Conversely, Rosenberg and Green (1989), in their review of 64 
treated cases from the world literature, found that with 
supportive measures only, the mean time for a clinical 
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response was 6-8 days while the addition of dantrolene reduced 
this to 1-2 days and bromocriptine to one day. 
Benzodiazepines 
Several investigators have reported transient relief of 
symptoms with benzodiazepines (Burke et al. 1981; Fricchione, 
1983; Lew & Tollefson, 1983; Morris, 1980). Rosebush and 
Stewart (1989), observed that patients needed benzodiazepines 
to ease discomfort and to decrease the hyperadrenergic state 
associated with the syndrome. 
The Use of Electroconvulsive Therapy (ECT) 
Hermesh et al. (1988), recommended ECT as a treatment option 
in the active phase of NMS, since four cases had a successful 
outcome . They concluded that due to the postulated ability of 
ECT to increase post synaptic receptor sensitivity to 
dopamine, this might explain its beneficial effect in NMS. 
Adityanjee (1987), challenged the recommendation of Hermesh et 
al. (1988), in the use of ECT as a specific treatment modality 
for NMS and cited two cases where cardiac arrest occurred 
during ECT, which resulted in permanent brain damage in one 
case. He concluded that the use of ECT is controversial and 
advocated the use of safer treatments such as bromocriptine 
and dantrolene. 






cases of NMS, Davis 




during or shortly after 
these with a group of 
treatment and concluded 
an episode of NMS. They compared 
controls who received no specific 
that ECT is probably safe in the 
treatment of NMS since no serious unexpected events occurred 
with its use during an episode, provided neuroleptics had been 
stopped. 
TREATMENT OF THE UNDERLYING PSYCHOSIS 
Challenge with Neuroleptics 
The probability of recurrence of NMS after recovery when 
challenged by further neuroleptic treatment was discussed by 
Wells et al. (1988). Of the 24 patients challenged, six 
showed a relapse of symptoms. The investigators noted that a 
'drug holiday' of more than five days before challenge with a 
further dose of neuroleptics, was related to a reduced 
likelihood of recurrence. 
They concluded that further neuroleptic treatment was an 
acceptable risk, if further treatment was needed. Rosebush et 
al. ( 1989) , also noted that a period of not less than two 
weeks after NMS before challenge or rechallenge was associated 
with success. 
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OUTCOME OF THE NEUROLEPTIC MALIGNANT SYNDROME 
Delay and Deniker (1968), characterized the syndrome as 
'malignant' due to a possible fatal outcome. Caroff (1980), 
in a review of the early literature, cited a mortality rate of 
20%. Levinson and Simpson (1986), in an analysis of 39 cases 
with extrapyramidal symptoms and fever, recorded three 
fatalities, which represented a mortality rate of 7,7%. Each 
death could be explained by recognisable medical complications 
rather than by a specifically neuroleptic induced mechanism. 
I n a review of 115 cases of NMS, Addonizio et al. ( 1987), 
found a mortality rate of 11%. Death resulted from medical 
complications that arose during the course of NMS such as 
pneumonia, renal failure, sepsis and pulmonary embolism. 
There were no fatalities in a prospective study of nine 
Chinese patients (Deng et al. 1990). Likewise, there were no 
fatalities and few sequelae in a series of 24 episodes of NMS 
despite the fact that all patients were extremely ill 
(Rosebush and Stewart, 1989). 
CONCLUSION 
It is clearly evident in this review of recent literature that 
many inconsistencies and uncertainties exist about the 
neuroleptic malignant syndrome, with particular regard to 
pathophysiology, diagnostic criteria, incidence, risk factors, 




A series of six consecutive cases who were admitted to the 
psychiatric emergency unit at Groote Schuur Hospital between 
May 1989 and November 1990 are described. 
Following the emergence of symptoms of the neuroleptic 
malignant syndrome, the patients were admitted to a medical 
ward under combined specialist management, which included a 
physician, a psychiatrist and a neurologist, supplemented by 
competent nursing. 
CASE ONE 
A 25 year old married Coloured female was admitted to the 
psychiatric emergency unit with a history of sudden onset of 
bizarre behaviour described as episodic mutism and withdrawal 
alternating with restlessness and incoherent speech. The 
patient had complained of feeling unwell for several days 
prior to onset of the behaviour change. 
On examination: She was noted to be pyrexial with a 
temperature of 37.6°, pulse rate 76/min, BP 130/70. 
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The patient was disorientated and agitated. She appeared 
perplexed and fearful and was incoherent: in addition there 
was posturing and waxy flexibility of the extremities. 
A differential diagnosis was made of delirious state or a 
dissociative disorder: she was admitted to a medical ward for 
further investigation. She required sedation on admission and 
was given Etomine 80mg i.v.i. and diazepam 10mg. i.v.i. 
Within 72 hours the patient became progressively more 
stuporous: this obtunded state alternated with restlessness 
and agitation. As she became more withdrawn and stuporous she 
required naso-gastric feeding and urinary catheterization. 
Investigations were as follows: 
CXR: Mild patchy consolidation left lower lobe ? due to 
aspiration. 
EEG: No abnormality 
L.P . No abnormality of CSF 
CT scan of head: Normal 
Electrolytes: No abnormality 
CPK: 11,000 I.U./L (Normal Range 50 to 110 I.U./L.) 
LDH: 579 units/L (Normal Range 175 to 350 units/L} 
AST: 56 units/L (Normal Range 7 to 25 units/L) 
Alk Phos: 87 I.U./L (Normal Range 30 to 70 I.U./L} 
FBC: White cell count 19x109/l . 
Toxicology Screen: Non contributory 
MSU: 3+ proteinuria (no myoglobinuria) 
Collagen screen: Normal 
Blood Culture: Negative 
V. D. R.L.: Negative 
Thyroid Function: Normal 
Course in Hospital 
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By day 5 the patient was very ill and examination showed: 
Temp . 39°c: PR 130/min: RR 30/min: Intermittent diaphoresis. 
MSE: Profound stupor 
Neurological: Generalized muscular rigidity ( lead pipe) 
associated with episodic involuntary movements involving all 
four extremities. At times she was noted to have a mild 
tremor of the extremities, pill rolling of both wrists and a 
coarse tremor of the tongue. Both glabellar tap and palmar-
mental reflex were positive. Tendon jerks were present but 
asymmetrical (L) to (R) Plantar reflexes. 
By day 7 her physical state had improved, but she remained in 
a markedly catatonic state. She was given Diazepam 10mg. i.v. 
with dramatic response in that she was able to give a coherent 
account of herself. She was orientated for person and place 
but not time. She gave information about her husband and baby 
and about her work at the factory. 
the diazepam interview she again 
Several hours following 
lapsed into a mute and 
catatonic state, refusing to feed herself and became 
incontinent of urine. A low grade temperature, tachycardia, 
diaphoresis and neurological signs persisted. 
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A provisional differential diagnosis was made of: 
? Neuroleptic malignant syndrome 
? Viral encephalopathy and delirium. 
Due to her obtunded mental state it was decided to proceed 
with ECT, which was given on day 9. 
observed as she became more alert 
Slight improvement was 
and was able to feed 
herself, although she remained withdrawn and uncommunicative. 
On day 14 she suddenly became agitated and was immediately 
given Etomine 40mg i.v. and Haloperidol 10mg. i.v. Within 24 
hours she was noted to have marked generalized muscular 
rigidity but she did not manifest any other clinical or 
laboratory abnormalities to indicate a relapse of the 
neuroleptic maligant syndrome. 
The clinical features of NMS resolved within 14 days but due 
to persistence of a psychotic mental state she was referred 
for admission to Lentegeur Psychiatric Hospital for further 
management of her psychotic state which was characterized by 
aggressive and irrational behaviour, nihilistic and 
persecutory delusions such as "I don't have a heart any more", 
"My boyfriend is going to kill the sister in the ward", "My 
mother says I'm too black to know what is going on". She was 
treated with clozapine 50mg. b.d. from Day 17 with no 
recurrence of NMS. 
Psychosocial Background 
During her admission to 
obtained from her mother 
GSH collateral 
who stated that 
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information was 
her daughter, a 
factory supervisor, recently married into a family of whom her 
own family strongly disapproved. At one stage she was 
disowned by the family for making the decision to marry. She 
had a baby of 6/12 and lived with her husband in the home of 
her in-laws. She seldom saw her mother. Her husband was 
reported to be a womaniser; he spent little time with his wife 
and baby. The patient was always a quiet, hard working and 
competent person. There was no previous psychiatric history, 
although she was a slow learner at school and left after 
completing Standard 4 at the age of 16. 
history. 
Family History: 
No past medical 
Father's uncle had an admission to a mental institution, 
diagnosis unknown. 
Course in Hospital at Lentegeur 
The patient was treated with Clozapine 25mg b.d. and after six 
weeks she made a sudden and dramatic recovery and was 
discharged home without medication. 
Follow-up: 
The patient has had no further problems at three years 
follow-up and functions well as mother, wife and as supervisor 
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in a factory. 
disorder. 
There are no residual features of a psychotic 
Final Diagnosis DSMIII-R 
Neuroleptic malignant syndrome in a patient presenting with a 
catatonic syndrome followed by a brief atypical paranoid 
psychosis. 
Axis I Catatonia/Atypical paranoid psychosis 
Axis II Deferred 




A 20 year old Xhosa male was admitted to the emergency unit on 
14.6.1989. The history given by his mother stated that he was 
unemployed and lived with her in Guguletu. He had been 
feeling unwell for a period of two weeks when suddenly four 
days before she brought him to hospital he became withdrawn, 
mute, stared into space and remained motionless for hours. At 
times he would become acutely fearful and agitated and ran 
around the home . He was brought to hospital in a state of 
psychomotor agitation and required sedation on admission. He 
was given Etomine 80mg. i.v. and Diazepam 10mg. iv. 
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On examination after sedation: 
Pulse rate 140/min: BP 120/80: Temp. 37.7°c. 
There was evidence of mild dehydration. A diagnosis of strange 
behaviour ? dissociative disorder was made in medical 
emergency and on day 2 he was ref erred for a psychiatric 
opinion. 
On examination in psychiatric emergency unit: 
Labile pulse rate 80 to 130/min: Labile BP 160/110 to 120/70: 
Temp: 37.5°c: Intermittent diaphoresis. 
On neurological examination he had waxy flexibility, 
posturing, and an obtunded mental state. 
On day 3 he suddenly became agitated and was given Etomine 
80mg. i. v. and Diazepam 10mg. i. v. Thereafter he became 
profoundly stuporous with marked autonomic instability, a low 
grade pyrexia of 37. s0 , generalized muscular rigidity, 
diaphoresis. 
Provisional Diagnosis: 






















LP : NAD 
EEG: Normal 10 hertz alpha background 
FBC: White cell count 7.5 xlO 9/L 
CT: Normal 
Toxicology Screen: NAD 
MSU: NAD 
Thyroid: NAD 
VDRL : Negative 
Course in Hospital 
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The patient required i. v. fluids and naso-gastric feeding to 
correct and maintain hydration and nutrition. He was treated 
with supportive measures only and was given Diazepam 10mg. 
i. v. for sedation when needed. He remained unresponsive and 
stuporous until day 5, when he suddenly improved and was more 
alert and communicative and was able to feed himself. 
Nasogastric feeding was discontinued. However, the patient 
remained restless and psychotic and a continued problem of 
containment. 
on day 6 he was given a small test dose of Clozapine (50mg.) 
with no ill effect. On day 10 he was transferred to Valkenberg 
Psychiatric Hospital for further management of his abnormal 
behaviour. At the time of referral he had persistent severe 
extrapyramidal signs and mild fluctuations of pulse and BP. 
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Course in Valkenberg 
He was treated with smal 1 doses of clozapine and made an 
uneventful recovery after six weeks. 
Psychosocial Background 
There was little information about this patient, but the 
mother stated that he had worked at S.A. Breweries until one 
month before admission to hospital, when he suddenly lost his 
job. He did not abuse substances, namely alcohol, dagga, 
rnandrax. He had no previous psychiatric history, nor had he 
been taking any medication. He had sustained a serious head 
i njury with concussion at age six, but there had been no 
sequelae. He had a Standard 7 education. 
Family History: 
Mother had recently been discharged from Valkenberg with a 
first psychotic breakdown at 40 years. She was taking 
chlorpromazine 100mg. daily. Diagnosis: ? Schizophrenia. 
Final Diagnosis 
Neuroleptic malignant syndrome in a patient presenting with 
catatonia followed by an atypical psychosis. 
Axis I Catatonia/ 
Atypical paranoid psychosis 
Axis II 





A 20 year old Xhosa male was admitted to the emergency unit at 
GSH on 9.6.1981. His father gave the history that the patient 
got up to go to work the day before admission and complained 
that "something was biting his legs". During the day he 
became quiet and withdrawn and later was noted to be mute, 
i mmobile and uncommun i cative. This behaviour was followed by 
the sudden onset of an acutely agitated state at which stage 
his family restrained him and brought him to hospital. 
Examination on admission: 
Temp: 36.4°: Pulse rate: 88/min: BP 140/90. 
He was catatonic, displaying waxy flexibility, posturing, 
mutism and negativism. 
Sedation was given for an episode of agitation following the 
i nitial mute state - Etomine 80mg. i.v.i. and Diazepam 10mg. 
i. v.i. 
Examination day 2: 
Temp. 37.5°: Pulse rate 120/min: BP 160/100. 
Neurological examination: Generalized increased muscular tone. 
MSE Mute and unresponsive. 
Examination day 3: 
Persistent tachycardia and labile BP: Temp. 
incontinence. Generalized muscular rigidity 
protrusion of the tongue. 
Mental State examination: Mute and unresponsive. 











CT of head: Normal 
Blood culture: Negative 
Toxicology Screen: NAO 
VDRL Negative 
HIV Negative 
FBC White cell count= 6.88 x 109/L 




Provisional diagnosis: In view of the clinical features and 
elevated CPK (mm) a diagnosis of Neuroleptic maligant syndrome 
was made. 
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Course in Hospital and management 
The patient remained stuporous and rigid from day 2 - 10. He 
continued to have a persistent tachycardia, fluctuating BP, 
Temp. 38° and intermittent diaphoresis. On day 5 he was given 
Atendol and Adalat in an attempt to control his autonomic 
signs, but there was little response. 
Throughout the illness the patient was maintained on i. v. 
fluids and nasogastric feeding. 
On day 9 his CPK had dropped to 387 I.U./L and there was some 
improvement in his general condition. He suddenly became 
restless at night and was inadvertently sedated with 
haloperidol 5mg. i.v. 
NB: This was followed by a rise in CPK to 1095 I.U./L on day 
10 and increased muscular rigidity. Ongoing management 
consisted of supportive measures only and diazepam 10mg. i.v. 
was given to control restless behaviour when necessary. 
Neurological Examination: 
In addition to generalized muscular rigidity which had a lead 
pipe quality, upper motor neurone signs developed in both 
lower limbs. Knee and ankle jerks were markedly increased and 




By day 12 the acute illness had settled but the catatonic 
state persisted. He was given ECT x 2 treatments and there 
was a gradual improvement in his mental state and mobility. 
By day 17 it was evident that he had an abnormal mental state 
with features of hypomania. It was observed that occasional 
episodes of autonomic instability and sweating per sisted, but 
CPK returned to normal levels and he remained apyrexial. In 
addition, there was residual parkinsonism, hyper reflexia of 
the lower limbs and generalized increased muscle tone. 
At this stage the patient was referred to Valkenberg Hospital 
for further management of his hypomanic state. He was treated 
with small doses of clozapine and discharged after six weeks. 
He has remained well at follow up visits and is functioning 
normally in his occupation as a garbage collector. 
Psychosocial History and Past History 
The information given by the father stated that the patient 
was a garbage collector in Khayelitsha and was presently 
residing with the father. 
There was no history of drug/alcohol abuse, and no history of 
fits or head trauma or previous medical history of note. 
There were no recent stressors, although the patient had 
always been a worrier and a poor achiever with a Standard 4 




Neuroleptic malignant syndrome in a patient presenting with 
catatonia followed by hypomania. 
Axis I Catatonia/first manic episode/Bipolar 
disorder 
Axis II 





A 48 year old Coloured female was admitted to the medical 
emergency unit at GSH on 6.8.1989 from Lentegeur Hospital with 
a diagnosis of "aphasia" ? due to cerebral vascular accident 
(CVA). The patient was a known non-insulin dependent diabetic 
of late onset. On admission a diagnosis of hysteria was also 
considered and she was referred to the psychiatric emergency 
unit for further assessment. She was noted to be mute and 
immobile and at times restless with incoherent speech. She 
was given chlorpromazine 100mg. intramuscularly for agitation 
and referred back to Lentegeur. 
She was sent back to GSH 24 hours later due to deterioration 
in her condition. A provisional diagnosis of an alcohol 
withdrawal state was suggested. 
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On examination: 
Temp. 38°: BP 160/120: Pulse Rate 90/min.: Resp. rate. 
20/min: sweating. 
Neurological: Mild coarse tremor noted of upper extremities 
associated with generalized muscular rigidity. 
Mental state was stuporous. 
Patient appeared mildy dehydrated. 
Investigation: 


























of blood glucose 
Neuroleptic malignant syndrome 
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Course in Hospital 
For the following eight days after admission the patient had a 
fluctuating temperature up to 38.5°: pulse rate 120/min: RR 
24/min: BP 170/120. 
There was intermittent diaphoresis and marked generalized 
muscular rigidity (lead pipe). 
Mental state stuporous and unresponsive. 
On day 8 the patient was given bromocriptine 5mg. t.i.d. with 
l ittle effect. The drug was discontinued on day 11. The 
patient was treated by supportive measures only with naso-
gasric feeding and intravenous lines. Glucozide 80mg. was 
administered 2 x daily via N/G tube. By day 12 there was a 
marked improvement in the patient's physical condition and 
mental state. The support lines were discontinued as the 
patient was able. to feed herself. 
rigidity was still noted by day 
The generalized muscular 
15, but the patient was 
mobile. By day 20 she had fully recovered from the NMS, but 
her mental state was noted to be depressed. She was 
apathetic, and cried frequently. She was given ECT x 3 for 
depression over the next ten days with little improvement 
noted. 
On day 30 she was referred to Lentegeur Hospital for further 
management of a depressive disorder. She was treated with 
amitriptyline and discharged after one month. 
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She remained well at follow up after two years, although 
complained of 
the illness. 
residual pain in the legs and feet following 
She continued to take medication for her 
diabetes and mild hypertension but discontinued 
antidepressants. 
Past History and Psychosocial History 
A neighbour gave collateral that the patient was a cleaner in 
a laundry. On the day of onset of the illness she had gone to 
work as usual when she suddenly became mute and unresponsive 
and was rushed to Lentegeur Hospital. 
There was no history of past psychiatric illness. There were 
no apparent stress factors except that her husband was 
unfaithful and she was often left alone at home. No past 








Major depressive episode 




A 33 year old Coloured f emale was admitted to the medical 
emergency unit from Piketberg on 11.10.89, with a one-day 
history of sudden onset of a mute and immobile state. She had 
been well previously and there was no past psychiatric 
history. In hospital she became acutely a g itated and 
incontinent and was sedated with Etomine 80mg. intraveneously. 
She was assessed in the psychiatric emergency unit as 'manic' 
and referred to Lentegeur hospital for admission. Two days 
later she was r eferred back to GSH in a stuporous and pyrexial 
condition with bizarre involuntary movements of the head and 
neck and facial muscles. It was noted that in Lentegeur she 
had received chlorpromazine 100mg. intramuscularly on two 
occas1ons. 
On examination: 
Temp. 38,5°: pulse 110/min: BP 130/80. 
Neurological: Generalized muscular rigidity. 
Episodic dystonic movement as described above. 
Mental state: stuporous and unresponsive. 
Mild dehydration. 
Investigations: 
FBC wee 16,62 x 109/L 
Enzymes: CPK 1662 I.U./L 
ALT 190 units/L 
CEUG: 
AST 127 units/L 
Na 157 mmol/1 
K 4,8 mmol/1 
Creatinine 130 umol/1 
Urea 20,8 mmol/1 
LDH 786 units/L 
EEG Generalized non-specific slowing 







CSF FTA Negative 
course in Hospital 
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The patient continued to man if est a fluctuating temperature, 
autonomic instability, intermittent diaphoresis, stuporous 
mental state and persistent generalized muscular rigidity with 
bizarre movement until day 10, when she began to improve 
gradually. 
She was managed with supportive measures and diazepam 5mg. 
b.d. When she had recovered from the acute illness there was 
no evidence of a residual psychiatric disorder. 




The patient was the wife of a farm labourer in the Piketberg 
area. She reportedly had an argument with her father the day 
before onset of the illness. There was no history of drug 
taking, alcohol, head injury or fits. There was no family 
history of psychiatric disorder. 
Follow-up 
The patient remained well at 3 years follow up. There has been 





Axis III Neuroleptic Malignant Syndrome 
Axis IV 
Axis V 
CASE REPORT 6 
Episode One 
A 33-year old woman of Malaysian origin was admitted to the 
psychiatric emergency unit in a profoundly stuporous and 
unresponsive state. On examination she was pyrexial, 
temperature 37,8 c, pulse rate 150/min, B.P. 150/100, 
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respiratory rate 36/minute. She had marked intermittent 
diaphoresis and generalized muscular rigidity. There was no 
evide nc e of dehydration. On investigation she had a raised 
CPK, (1185/IU/L) and a raised white cell count (16,9x10 /1). 
Toxicology screen, chest x-ray, lumbar puncture, blood 
culture, MSU, EEG, C-T scan were normal. 
Collateral information obtained from the patient's family 
stated that she had been taking chlorpromazine, 25mg at night, 
one month before admission. During that period she had 
developed increasing stiffness of the limbs and had become 
progressively withdrawn, fearful and agitated. Three days 
before admission she had deteriorated into a mute, immobile 
and rigid state. Because the presenting clinical picture 
emerged during the administration of chlorpromazine, a working 
diagnosis of NMS was made. The stuporous mental state and 
muscular rigidity responded dramatically to the administration 
of diazepam ( 20mg i. v. ) al though autonomic instability and 
mild pyrexia persisted. Thereafter she was maintained on oral 
diazepam (5mg six-hourly). Within 7 days she was asymptomatic 
and CPK and wee had returned to normal levels. There was no 
evidence to support either a schizophreniform or an affective 
disorder prior to or during the illness or at t he time of 
discharge. She was discharged home after 7 days on diazepam 
( 5mg three times daily). It was noted in hospital records 
that during the past 10 years she had had three undiagnosed 
episodes of mutism and unresponsiveness during each of which 




The patient was readmitted to the emergency unit 27 days later 
with a two-day history of mutism and immobility. on 
examination she was pyrexial, temperature 37,5 c, pulse rate 
130/min . , B.P. 150/100, respiratory rate 30/minute, and she 
was sweating. There was no dehydration and no muscular 
rigidity. On investigation, CPK was raised to 450 IU/L and 
she had a raised white cell count of 22,000 x 10 /L. 
Toxicology screen, CSR, lumbar puncture were normal. The only 
medication she had used was the prescribed diazepam (5mg three 
times daily) which she had discontinued a week following her 
previous discharge. She had not taken any neuroleptics nor 
other psychotropic agent, except diazepam. 
A diagnosis of catatonia was made. The stuporous and immobile 
state altered to acute agitation after 24 hours, at which time 
she was inadvertently given haloperidol 10mg. i.v. for 
sedation. Within six hours she became profoundly stuporous 
once more, with marked diaphoresis, temperature 0 38,5 C, 
tachypnoea, and a persistent tachycardia of 150-160/min. Two 
additional features appeared, namely, muscular rigidity and a 
extremely elevated CPK (11,540 IU/L). The administration of 
diazepam (20mg i.v.) resulted in an immediate and dramatic 
resolution of the stupor and muscular rigidity. The patient 
was maintained on diazepam (20mg orally six-hourly) and 
remained mobile, alert and co-operative. 
The autonomic instability persisted but gradually resolved 
over several days during which period the CPK and wee returned 
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to normal levels. The patient was discharged home recovered, 
7 days after admission, on diazepam (5mg. three times a day). 
An appointment was given for follow-up. 
Episode 3 
The patient was readmitted to hospital a year later with a 
history of the acute onset of a mute and unresponsive state. 
She had defaulted from follow-up and had not taken diazepam or 
any other medication for approximately six months. 
On examination she was mildly pyrexial, temperature 37 ,·5°e, 
pulse rate 120/minute, respiratory rate JO/minute. 
Intermittent diaphoresis was noted. There was no muscular 
rigidity. She was negativisitic, mute and posturing. 
On investigation she had a raised ePK (395 IU/L), a normal wee 
(8,5xl0 /L) and low serum Iron [Iron 6 UMOL/L (normal 8-30); 
TIBe 65 UMOL/L (normal 48-67); % saturation 11% (normal 18-
52)]. [An additional investigation of serum iron was carried 
out in view of a recent study (Rosebush & Mazurek, 1991) who 
noted frequent occurrence of a low serum iron concentration 
with the NMS.] 
The patient's catatonic state responded well to diazepam 
intravenously, and thereafter she was maintained on oral 
diazepam and supportive care as in previous episodes. The 
autonomic dysfunction settled and ePK and Iron studies 
returned to normal levels within seven days. 
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SUMMARY OF CASE REPORTS 
The six patients described presented to a local teaching 
hospital with an illness of acute onset, 
mute and immobile state alternating 
characterized by a 
with psychomotor 
agitation. There were four females and two males, with ages 
ranging between 20 years and 46 years. Five patients had no 
previous psychiatric history. 
Following neuroleptic exposure all of them developed the 
clinical features characteristic of the neuroleptic malignant 
syndrome, namely an a l tered state of consciousness, muscular 
rigidi ty, pyrexia, autonomic instability, diaphoresis, as well 
as the laboratory findings of elevated CPK levels and 
leukocytosis (in 4 patients) which are commonly associated 
with the syndrome. 
Iron studies undertaken in patient 6 showed a low serum iron 
concentration. 
Four of the patients had no evidence of coi:icurrent illness 
prior to the onset or during the NMS; one had radiographic 
evidence of patchy consolidation in the left lung and another 
had non-insulin dependent diabetes mellitus. Two had evidence 
of mild dehydration. 
All patients were extensively investigated for a medical 
illness. Investigations included chest x-ray , VDRL , 
urinalysis, toxicology screen, blood culture, lumbar puncture, 
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EEG, C-T scan, serum biochemistry, full blood count, collagen 
screen. 
Five patients had had no previous exposure to a neuroleptic 
nor any other form of psychotropic medication before admission 
to hospital. Patient 6 had been taking chlorpromazine 25mg. 
daily for a period of one month before admission. 
All patients manifested the features of catatonia prior to 
neuroleptic administration. 
The diagnosis of catatonia was based on DSM-III-R criteria for 
c atatonia. The clinical features were consistent with 






The neuroleptics administered 






Features of NMS emerged within 30 to 72 hours following 
administration of a single dose of a neuroleptic agent in 
patients 1 to 5. 
All patients were managed with medically supportive measures 
during the acute illness. Various treatments were administered 
r andomly during the acute phase as follows: Benzodiazepines 
had dramatic but short-lived effect in patient 1 and patient 
6. Bromocriptine was prescribed for patient 4 with no effect. 
ECT x 2 administered to patient 1 during the acute phase of 
i llness appeared to prevent deterioration. ECT administered 
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to patients 3 and 4 during the recovery phase was of doubtful 
benefit. 
All patients had an uncomplicated course with no life-
threatening sequelae. Duration of acute illness ranged from 5 
to 14 days. Residual features of parkinsonism and mild 
fluctuations of pulse and blood pressure persisted for up to 
28 days in some cases. 
Following recovery two patients (5 and 6) had no evidence of 
psychiatric disorder. Two patients (3 and 4) had features of 
an affective disorder. Two patients had an atypical psychosis 
(1 and 2). Patients 1, 2, 3 and 4 were referred t o another 
institution for management of the residual psychiatric 
disorder. Since patients 5 and 6 showed no residual 
psychopathology after NMS they were discharged home. 
Following the acute illness, patients 1, 2 and 3 were 
challenged with clozapine for psychotic disorders between days 
14 and 20 (with no ill effect). Patients 5 and 6 were 
discharged on small doses of diazepam. Patient 4 was treated 
with amitriptyline and ECT following the acute phase of NMS. 
Two of the patients (3 and 6) showed intensified features of 
the NMS when neuroleptics were reintroduced during the acute 
phase of the illness. Patients 1 to 5 have remained well at 
follow-up and none is taking psychotropic medication. Patient 
6 had a further relapse of catatonia (unassociated with 





The pathogenesis of the neuroleptic malignant syndrome and the 
predisposing/risk factors for the development of the syndrome 
are unclear. Numerous case reports and several retrospective 
analyses of chart data in the past decade have not only 
popularized the syndrome, but have also confused the clinician 
with disparate views concerning definition, aetiology, 
prevalence, pathogenesis and management of the disorder. 
Recent prospective studies (Addonizio, 1986; Deng et al. 
1990; Rosebush & Stewart, 1989) have contributed more useful 
and consistent findings concerning the syndrome. 
The outstanding feature in this group of patients was the 
catatonic state of acute onset (prior to neuroleptic exposure) 
which appeared to herald the emergence of the neuroleptic 
malignant syndrome. 
Controversy exists concerning the relationship of NMS to 
catatonia. Some writers have attempted to define the syndromes 
as separate pathological entities (Castillo, 1988; 
Fleishhacker, 1989), whereas others have claimed that the 
similar clinical features 
(Kellam, 1987; 
The finding of 
Mann et al. 
suggest 
1986; 
an acute catatonic 
a common pathophysiology 
Price & Turnbull, 1989). 
state in these patients, 
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prior to neuroleptic administration, supports the latter 
hypothesis. It is suggested that attempts to distinguish 
between the syndromes may be erroneous and mislead clinicians 
working in this field. 
CLINICAL PRESENTATION 
Patients 1 to 5 and patient 6 ( episodes 2 and 3) presented 
with an initial illness of acute onset which was characterized 
by mutism, immobility, posturing, waxy fl exibility, and 
negativism. This state alternated with episodes of acute 
psychomotor agitation and incoherence. 
Following the meticulous piecing together of the examination 
and investigatory findings, with the preadmission information 
from family members and previous hospital data, the cluster of 
catatonic features emerged as the consistent and common 
finding in all patients "prior" to neuroleptic administration. 
This observation has not previously been reported. Other 
investigators have noted that catatonia forms part of the 
symptom complex of NMS, usually reported as "following" 
exposure to neuroleptics (Addonizio, 1980; Fricchione, 1987; 
Rosebush, 1989). 
Every patient in this group presented with episodes of 
"catatonic mutism", followed by psychomotor agitation which 
was attributed to a phase of "catatonic excitement" . During 
the episode of excitement [psychomotor agitation) ; a 
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neuroleptic was administered in order to control behaviour; 
thereafter the patients developed a profoundly mute and 
stuporous state with autonomic instability, diaphoresis, 
pyrexia and extrapyramidal signs such as muscular rigidity in 
every case, and movement disorders of the extremities in some 
cases. These features are characteristic of the disorder that 
has been termed the neuroleptic malignant syndrome. 
It is possible that the psychomotor agitation noted by others 
(Harsch, 1987; Itoh et al. 1977; Keck et al. 1989; Rosebush & 
Stewart, 1989) may have been part of a catatonic syndrome in 
the observed patients. It is suggested, therefore, that 
certain patients are admitted to hospital in a state of 
catatonic excitement (psychomotor agitation) , are given 
neuroleptics to contain their behaviour and go on to develop 
an intensified catatonic state, with the additional feature of 
neuroleptic induced muscular rigidity, which is then diagnosed 
as the NMS. 
This was exemplified by patient 6, in that her initial 
catatonic presentation, which included muscular rigidity, was 
associated with neuroleptic exposure prior to admission to 
hospital and therefore a diagnosis of NMS was favoured. 
However, the clinical features of the second catatonic episode 
were also indistinguishable from those of the first episode, 
except for muscular rigidity which was notably absent. During 
the second episode, muscular rigidity only appeared following 
the administration of a single dose of haloperidol, which was 
inadvertently given to control psychomotor agitation. In 
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of catatonia in this episode were 
exposure to haloperidol, namely, 
and stupor. CPKmm levels also rose 
In reviewing individual reports in the literature, many of the 
cases described may have had a catatonic syndrome prior to the 
diagnosis of NMS: 
Kish et al. (1990); Cases 1 and 5 
Levenson et al. (1990); Cases 1 and 
Levenson, 1985; case 1 
Castillo, 1989; Cases 1 and 2 
Das Gupta (1991); Case Report 
Singh et al. 1989; Case Report 
Thacker et al. (1990) : Case Report 
Kemperman, 1989: Case Report 
Otani et al. (1991) ; Case Reports 
Goldwasser et al. 1989 : case Reports 
Chayasirisabhon et al. 1983 : Case Report 
Hermesh et al. 1987 Case Report 
Shalev et al. (1988) : Case Report 
Goeke et al. (1991) : Case Report 
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LABORATORY FINDINGS 
Traditionally the diagnosis of NMS has been made on clinical 
grounds and the non-specific laboratory findings of raised 
serum creatine phosphokinase (CPK) and leukocytosis being of 
supportive value in confirming the diagnosis. Recently 
Rosebush and Mazurek (1991), noted that a low serum iron 
concentration might also be associated with the syndrome. 
CPK is found in muscle and brain tissue and provides a measure 
of tissue catabolism. There are three isoenzymes of which 
CPKmm most closely reflects muscle activity and integrity. 
CPKmm may be raised by skeletal muscle damage ( as found in 
intramuscular injections, exercise, trauma and massage) and by 
some drugs, including succinylcholine alcohol and lithium. It 
is also raised in malignant hyperthermia, coma, infections, 
diseases involving muscle, convulsions, hyperthyroidism and 
possibly muscular rigidity. 
In severe cases of NMS, rhabdomyolysis may cause 
myoglobinuria, and result in renal failure. In such cases 
CPKmm is drastically elevated with levels exceeding 30,000 
I.U./L (normal level 50-110 I.U./L). The patients' described 
in this study showed moderately raised levels of CPK mm (range 
622 to 1150 I. U. /L) . None of the patients had received an 
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intramuscular injection and there was no evidence of 
myoglobinuria. However, all six patients had muscular rigidity 
and therefore it would be logical to assume that elevated 
CPKmm in these cases was due to this rigid state. However, it 
is pertinent to note that patient ' 6 had a raised CPKmm level 
during the second catatonic episode prior to neuroleptic 
exposure and there was no clinical evidence of muscular 
rigidity. Following a single dose of haloperidol, the CPKmm 
rose dramatically and muscular rigidity appeared for the first 
time. The raised CPKmm, in the absence of rigidity in this 
instance, and the presence of persistent rigidity with normal 
CPKmm levels in patients 1, 2, 3 and 4 in the recovery phase 
indicate that CPKmm cannot be reliably attributed to rigid 
musculature. 
It is suggested that an elevated CPKmm is not related to 
muscle rigidity but is indicative of the underlying catabolic 
process which is part of the catatonic syndrome preceding the 
NMS. It would appear that neuroleptics do not precipitate 
this process but in some cases, intensify the catabolic state 
of the antecedent catatonic syndrome as was demonstrated by 
patient 6 (episode two). 
our cases demonstrated that CPKmm levels were not an indicator 
of severity of illness as all patients were profoundly ill 
with marked stupor, autonomic dysfunction and muscular 
rigidity and yet the CPKmm level was 
( 6 2 2 to 118 5 I . U. /L) , and there 
myoglobinuria. 
only moderately raised 
was no evidence of 
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However, the CPKmm level was useful in confirming the 
diagnosis and in monitoring the acute phase of the illness: a 
rising CPKmm indicated an ongoing pathophysiological process 
whereas a falling CPK signalled the onset of recovery as 
became evident in the associated improvement of their clinical 
status. It is important to note that following the acute 
phase of NMS, some of our patients ( 1, 2, 3 and 4) remained 
markedly parkinsonistic with muscular rigidity for a period of 
days to weeks, with normal CPKmm levels. 
Levenson ( 1985), included an elevated CPKmm as one of the 
three major criteria of 
inf erred that a raised 
diagnostic importance in NMS 
CPKmm differentiates NMS 
and 
from 
catatonia. This study suggests that a raised CPKmm does not 
differentiate NMS from catatonia, but instead highlights the 
similarity between the two syndromes. 
Serum Iron 
Rosebush and Mazurek (1991), recently reported that out of 26 
episodes of NMS, in 25 ( 96%) there was a dramatic fall in 
serum iron concentration in patients during the acute phase of 
the illness; this returned to normal in the recovery phase. 
Unfortunately, this investigation was not done in five 
patients in this study, but in view of the above report, serum 
iron studies were carried out during the third catatonic 
episode in patient 6. A low serum iron concentration was 
observed during this episode of catatonia ( unassociated with 
56 
neuroleptics), which returned to normal during the recovery 
phase. 
Hypoferraemia is known to occur in febrile conditions, 
strenuous exercise, and in myocardial infarction as part of an 
acute phase reaction (APR). Rosebush and Mazurek (1991), have 
postulated that NMS may be an acute phase reaction (APR) . 
This is a complex physiological response, which sets off a 
wide range of events including fever, leukocytosis, muscle 
breakdown and hypoferraemia: these are all characteristic of 
the NMS. They stated that the mechanism by which the APR 
might be initiated in NMS is unclear. The finding of a low 
serum iron concentration in our catatonic patient 
(unassociated with neuroleptics) suggests that the APR may be 
a physiological disturbance associated with a catatonic state. 
It is probably incorrect, therefore, to assume that the APR is 
a pathognomonic feature of NMS. If this response is common to 
both catatonia and NMS, it highlights the similar 
pathophysiology of the two disorders. 
PATHOPHYSIOLOGY 
The Role of Dopamine 
There is evidence that NMS may be related to a central 
dopamine deficiency 
mesolimbic pathways. 
predominantly in the 
Altered dopaminergic 
anterior hypothalamus may account for 
nigrostriatal and 
activity in the 
the autonomic 
dysfunction and hyperthermia ( Horn et al. 1988; Fricchione, 
1985; Mueller, 1983). 
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Reduced dopaminergic transmission in the diencephalon has also 
been postulated to explain the hyperthermia and catatonic 
signs described in lethal catatonia (Christot.tels, 1970; Kick, 
1981; Powers et al. 1976; Talsma, 1967). 
If a hypodopaminergic state exists in catatonic patients, it 
would be logical to assume that this deficiency would be 
aggravated by the dopamine blockade imposed by neuroleptics. 
This hypodopaminergic crisis in certain neurotransmitter 
pathways then manifests with the clinical features recognized 
as the NMS. 
The role of Serum Iron 
Recently, considerable attention has been given to the role of 
·serum iron and the maintenance of normal dopaminergic function 
in the brain. Iron is present in relatively large quantitites 
in the brain and its distribution roughly parallels that of 
dopamine with highest concentrations in basal ganglia (Ben-
Shacher, 1985). There is evidence that iron may be integral 
to normal function of the dopamine (D2) receptor. Rats made 
iron deficient have a reduced response to the dopamine 
mediated behavioural and physiological effects of apomorphine 
and have fewer D2 receptors without any apparent change in Dl 
receptors. 
Clinical studies have further demonstrated the association 
between serum iron and D2 receptor function. The "restless 
legs" syndrome is associated with iron deficiency anaemia. 
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This syndrome has been identified as virtually identical to 
neuroleptic induced akathisia, which is thought to be related 
to D2 receptor blockade (Editorial: Lancet, 1986). 
Rosebush and Mazurek (1991), suggested therefore that a 
decrease in serum iron may lead to a decrease in D2 receptors 
in the brain. In the presence of further dopamine blockade by 
neuroleptics, this further loss of receptors may trigger an 
acute reduction of dopaminergic function, thereby potentially 
contributing to the clinical features characteristic of the 
NMS. They contended that serum iron may be a useful 
biological marker for the NMS and a helpful adjunct in the 
diagnosis of the disorder. 
The additional finding of a low serum iron concentration in 
the third catatonic episode in patient 6 (unrelated to 
neuroleptics) is therefore highly pertinent and highlights 
again the similar pathophysiology between NMS and 
catatonia. 
This finding casts doubt on the usefulness of a low serum iron 
as a useful biochemical marker for NMS as suggested by 
Rosebush and Mazurek (1991). A low serum iron concentration 
may be a feature of catatonic states in general rather than 
the NMS per se. 
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Malignant Hyperthermia (MH) and the Neuroleptic Malignant 
Syndrome (NMS) 
Controversy exists concerning a possible pathophysiological 
relationship between NMS and MH. 
Both syndromes are characterized by fever and delirium, a 
hypermetabolic state of skeletal muscle and rhabdomyolysis. 
The possibility of an aetiological connection has been 
strengthened by reports of abnormal contractile response of 
skeletal muscle in vitro to halothane exposure in patients who 
developed NMS. Although theories of a neurogenic origin were 
proposed, evidence indicates that malignant hyperthermia is a 
disorder affecting skeletal muscle in which the concentration 
of calcium in the myoplasm rises uncontrollably during 
exposure to triggering drugs such as halothane and 
succinylcholine. The NMS is postulated to be a disorder of 
central neurogenic origin precipitated by the dopamine 
blocking activity of neuroleptics on dopaminergic 
neurotransmitter pathways in the brain. 
Due to the skeletal muscle response to halothane in 5 of 7 
cases of NMS, Caroff et al. ( 1987) , postulated that the 
development of rigidity in NMS is a function of a similar 
skeletal muscle abnormality as in malignant hyperthermia 
patients, triggered by neuroleptics. None of the NMS /MH or . 
control group in the study showed a significant difference in 
response to fluphenazine. This finding suggests that although 
NMS . patients may be MH susceptible, the converse does not 
apply. 
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Tollefson, (1982) , Scarlett (1983) and Merry et al. (1986) , 
reported contrasting evidence for MH susceptibility in NMS, in 
observing that the tissue from NMS patients did not respond 
abnormally to halothane, 
evidence indicates that 
caffeine or other agents. Clinical 
NMS patients tolerate anaesthetic 
agents without incident (Levenson et al. 1987, 1988; Lostra et 
a l. 1983). Adityanjee (1988), desc.ribed a case of NMS in a 
young girl who was given ECT x 6 under general anaesthesia 
with exposure to succinylcholine with no adverse effect. 
Goeke et al. (1991), administered ECT x 13 under general 
anaesthesia to a 42-year old female following NMS. In every 
anaesthetic the patient was given intravenous methohexital, 
succinylcholine and labetolol. The CPKmm, serum potassium and 
temperature were monitored during each ECT and remained 
stable. 
Three of our patients were given ECT under general anaesthesia 
in the recovery phase of NMS, which totalled seven exposures 
to thiopentone and succinylcholine and there were no adverse 
effects. Specifically there was no evidence of fever, rigidity 
or elevated CPKmm during or following the anaesthetic 
exposure . 
We have provided clinical and laboratory evidence which 
suggested that NMS and catatonia share a common 
pathophysiology. Based on clinical and laboratory 
similarities, Caroff et al. ( 1987) , have postulated a 
pathophysiological link between NMS and MH. If NMS is a 
neuroleptic in tens if ied form of catatonia as we have 
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postulated, then according to Caroff's hypothesis it would be 
logical to assume that catatonic patients may be MH 
susceptible. It is interesting to note, however, that ECT 
~nder general anaesthesia has historically been the treatment 
of choice for catatonia, but to date there have been no 
adverse consequences reported, specifically any occurrence of 
MH, following exposure of catatonic patients to anaesthetic 
agents. Likewise, not a single case of MH has been reported 
in the literature in NMS patients exposed to MH triggering 
agents . 
Despite the persuasive clinical data, anaesthetists continue 
to view NMS with a high index of suspicion and avoid the use 
of triggering agents such as succinylcholine in known NMS 
patients. 




several authors have commented that a ffective disorder is a 
common antecedent diagnosis in patients who develop NMS, and 
that patients with schizophrenia have the lowest incidence of 
NMS (Addonizio et al. 1986; Keck et al. 1987; Levenson et al. 
1988; Rosebush & Stewart, 1989). 
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The finding of a low incidence of NMS in patients with 
schizophrenia may be explained by the hyperdopaminergic state 
postulated as the underlying neurochemical imbalance in 
schizophrenia which may be a protective factor against the 
deleterious effects of neuroleptic induced dopamine blockade. 
Furthermore, ~tudies have shown an infrequent association 
between catatonia and schizophrenia. 
Initially, the patients with catatonia in this study were not 
assigned to another diagnostic category since none had a known 
previous psychiatric history. Following the acute illness, 
two patients were eventually diagnosed as having an affective 
disorder, two had an atypical psychosis and two patients had 
no residual psychopathology: there were no patients with 
schizophrenia. 
These findings are in accordance with those of other 
investigators (Abrams et al. 1976; 
et al. 1990; Mann et al. 1986), 
Barnes et al. 1986; Kish 
who have suggested that 
catatonia appears to be an acute neuropsychiatric syndrome of 
limited duration, which may arise during the course of an 
affective disorder, organic disor~er or from an undetermined 
aetiology. Catatonia is classified under the schizophrenic 
disorders in DSM III-R and ICD 9. Due to this historical 
classification, a diagnosis of catatonia has been universally 
considered to be synonymous with that of schizophrenia. This 
is unfortunate since patients such as those described above, 
who present with catatonia, are at risk for being diagnosed as 
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having schizophrenia, which is not only erroneous, but may 
serve to stigmatize the patient. 
Psychotropic medication and NMS 
All neuroleptics, including the newer generation drugs such as 
clozapine , have been documented as causal agents in the 
development of the NMS (see literature review). Keck et al. 
(1989), have suggested that the rate of neuroleptic dose 
increase and maximum neuroleptic dose administered may 
represent significant risk factors for the development of the 
syndrome. Rosebush (1989), suggested that the introduction of 
neuroleptics for the first time, or a dosage increase in a 
person, who is vulnerable, may account for the development of 
the NMS. 
Our patients had no previous exposure to neuroleptics and 
received only one or two doses of medication. The 
neuroleptics administered to these patients included 
clothiapine , chlorpromazine and haloperidol. The findings 
support those of Rosebush (1989), as the emergence of NMS in 
all patients appeared to follow the initial introduction of 
neuroleptics. In view of these findings, it is probable that 
the vulnerable state referred to by Rosebush is the antecedent 
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catatonic state which predisposes such patients to the 
deleterious effects of even a single dose of neuroleptic 
agent. 
Genetic factors 
Otani et al. ( 1991) , postulated that NMS may be genetically 
transmitted. They described the findings in a Japanese family 
where the mother and two daughters were noted to have had 
separate episodes of catatonia (not associated with 
neuroleptics), severe neuroleptic induced extrapyramidal 
symptoms and episodes of NMS. They concluded that the 
predisposition to NMS may be trait dependent. 
Patient 6, in this series demonstrated similar features with 
episodes of catatonia which were diagnosed as NMS only when 
associated with neuroleptics and the presence of muscular 
rigidity. If NMS is a catatonic state intensified by 
neuroleptic administration as suggested previously, then 
certain patients may have a trait dependent predisposition to 
catatonia, which manifests as NMS following neuroleptic 
exposure. 
CNS Disorders 
Several authors have commented on the association of the NMS 
with underlying brain disorders, other than psychiatric 
disorders. Fricchione ( 1985), and Rosebush ( 1989) J suggested 
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that CNS compromise may increase the risk of developing NMS. 
The CNS disorders include mental retardation, Alzheimer's 
disease, Cerebral vascular accident, Post-traumatic brain 
syndromes, seizure disorders and AIDS. None of these patients 
were found to have any associated CNS pathology prior to the 
onset of illness. 
Differential Diagnosis 
Patients who present with the cluster of clinical features 
suggestive of NMS require thorough investigation to exclude 
other causes of pyrexial and stuporous states. 
To exclude drug toxicity, dehydration and infections, all 
patients were screened by investigations which included 
toxicology screen, urinalysis, mid-stream urine; chest 
radiography, V.D.R.L., full blood count, cerebro-spinal fluid, 
Electroencephalogram, C-T scans, and serum biochemistry. 
Patient 1 had radiographic evidence of patchy consolidation in 
the left lung. Consequently a pneumonic process with 
septicaemia was considered to be a contributing factor to the 
physical state. However, this finding could not account for 
stupor and neurological abnormalities of muscular rigidity and 
tremor: the pneumonia was probably a sequel to the initial 
illness. 
Patient 4 had late onset diabetes mellitus and essential 
hypertension. A diagnosis of a cerebral vascular accident 
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(C.V . A.) was considered to be a possible cause of aphasia. As 
other signs appeared, such as tachycardia, l abile blood 
pressure and sweating, an alternative diagnosis of an acute 
.alcohol withdrawal state with delirium was considered. Certain 
features of NMS resemble the alcohol withdrawal syndrome with 
delirium (autonomic arousal, sweating, tremor, incoherence) , 
but this diagnosis is not usually accompanied by stupor, 
extrapyramidal signs and raised CPK levels, which emerged in 
this patient. 
The patient's diabetes and blood pressure were well 
controlled, and investigation ruled out C.V.A. as a cause of 
mutism. A blood count and liver profile provided no evidence 
for alcoholism. 
Central Nervous System Infection was considered as a possible 
cause of illness in every case . Lumbar puncture, V. D.R. L. , 
E.E.G. and C-T scan were carried out and proved to be non-
contributory. Case 5 was investigated for neurosyphilis due 
to the F.T.A. and an abnormal E.E.G., but the CSF was normal 
and the non-specific E.E.G. findings were attributed to a 
metabolic encephalopathy accompanying the catatonic state. 
Dehydration has been cited as a possible predisposing factor 
for the NMS. Rosebush and Stewart ( 1989) found dehydration 
present in 96% of theircases. Two of our group presented with 
mild dehydration which preceded the onset of NMS. It is 
difficult to determine if this factor contributed to the 
severity of the illness. The patients who were not dehydrated 
had as severe an illness as the two presenting with 
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dehydration. The correction of fluid and electrolyte balance 
in these cases was not associated with clinical improvement. 
It appears that dehydration does not have a role in the 
pathophysiology of the disorder, but is an associated feature 
which may complicate the course of the illness. 
MANAGEMENT OF THE NEUROLEPTIC MALIGNANT SYNDROME 
All patients recovered and did not develop medical 
complications during the course of illness, apart from the 
single instance of pneumonia. The uneventful outcome can be 
attributed to early recognition of the disorder and timely 
intervention along the following lines: 
General Measures in Treatment of NMS 
* Once the diagnosis is suspected, it is recommended that 
all patients be admitted to a medical ward for the 
management of the acute phase of the illness. 
* Fluid and electrolyte balance requires urgent correction 
and thereafter intravenous maintenance. Nutrition is 
maintained via nasogastric feeding during the stuporous 
and immobile phase of illness. 
* Neuroleptics must be immediately discontinued. 
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* Urinary catheterisation during the acut e phase of illness 
permits the moni taring of urinary output and the 
recognition of abnormal constituents such as myoglobin. 
* Daily serum samples are taken for the measurement of 
electrolytes, urea, creatinine, serum iron, CPK and white 
cell count. 
* The rigid and immobile physical state predisposes the 
patient to complications such as aspiration and 
hypostatic pneumonia, and deep vein thrombosis. 
Physiotherapy is therefore an important adjunct in the 
prevention of these potentially life-threatening 
complications. 
* Once the diagnosis of NMS has been established, it is 
useful to monitor progress by recording daily clinical 
and investigatory data on a flow sheet. 
These patients were managed by a combined multidisciplinary 
team consisting of a physician, a psychiatrist, psycho-





in the treatment of the 
is of limited or 
NMS. Specifically, 
there is inconsistency about the efficacy of drugs such as 
bromocriptine and dantrolene. In an overview, Fricchione 
(1985), advocated the use of benzodiazepines due to the 
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dramatic, although short-lived, response noted in some cases 
of NMS. Rosebush and Stewart (1989), recommended using 
benzodiazepines as part of treatment to relieve the patient's 
discomfort and to decrease the hyperadrenergic state which, 
they claimed, may contribute to the pathophysiology of the 
disorder. 
Benzodiazepines 
I n the management of our group of patients, supportive care 
was the mainstay of treatment, but diazepam was prescri bed 
where necessary for those patients who were restless and 
required sedation. Patient one showed a dramatic but temporary 
i mprovement in mental state following an intravenous dose of 
this agent which was given for diagnostic purposes. 
Patient 6 had a similar response to intravenous diazepam in 
every catatonic episode. Following the initial intravenous 
dose, a daily oral regime was prescribed, which maintained the 
i mprovement in mental status. Diazepam also improved muscular 
rigidity, but other features such as autonomic instability, 
pyrexia and raised muscle enzymes persisted and eventually 
resolved independently of the diazepam administration. 
We found that benzodiazepines played a valuable role in the 
responsive patient in early mobilisation and autonomy in the 
areas of promoting feeding and self-care, thereby preventing 
possible life threatening sequelae. 
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I share the view of Menza and Harris (1989), who 
commented, in an overview of the role of benzodiazepines in 
catatonic states, that agents such as diazepam and lorazepam 
have a role in the evaluation and management of the catatonic 
patient. 
It is important to emphasize, however, that the 
benzodiazepines do not appear to have an effect on the core 
metabolic dysfunction of the disorder. 
Bromocriptine 
Bromocriptine was prescribed for patient 4 (10mg. t.i.d.) over 
a period of three days with no apparent beneficial effect, and 
was therefore discontinued. ( Being a dopamine agonist, this 
agent may have the adverse effect of inducing or worsening 
psychotic illness.) 
Dantrolene Sodium 
Dantrolene [used intravenously in doses of 50mg. 12 hourly, up 
to 7 doses] , a skeletal muscle relaxant, was not prescribed 
for any of our patients. (Apart from inconsistent reports of 
efficacy in NMS, this drug has the potential problem of 
causing hepatic toxicity.) 
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ECT should be used cautiously and not as the treatment of 
choice during the acute phase of illness. However, where 
·there is a deterioration in the clinical state of the patient 
following supportive treatment as demonstrated in patient 1, 
ECT may be considered. 
The evidence concerning the safety and efficacy of this 
procedure remains largely anecdotal and requires further 
investigation. 
TREATMENT OF THE UNDERLYING PSYCHIATRIC DISORDER FOLLOWING 
RECOVERY FROM NMS 
Challenge with Neuroleptics 
Evidence has accumulated which suggests that certain patients 
resume neuroleptic therapy successfully with no sign of 
recurrence of NMS (Levenson & Fisher, 1988; Pope et al. 
(1990). Of particular note are the findings of Rosebush and 
Stewart (1989), who successfully challenged 13 (87%) of their 
15 patients. Five of the fifteen patients had a recurrence of 
symptoms when challenged initially. Four of these were re-
challenged with symptoms developing in two cases, finally one 
of these was successfully challenged a third time without 
recurrence of symptoms. Analysis showed that a period of over 
two weeks before re-challenge was significantly associated 
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with success. Their study showed that a lower drug potency 
and dosage at challenge were not statistically significantly 
related. 
The observations made in this study of 6 patients are in 
In some cases the accordance with the above findings. 
challenge was accidental, e.g. patient 
challenged with haloperidol on day 9 







symptoms. However, there was no sign of a recurrence when 
deliberately re-challenged -with clozapine on day 18 during the 
recovery phase. 
Patient 6 was also inadvertently given a doze of haloperidol 
during the second catatonic episode, which caused an 
in tens if ied catatonic state. CPKmm levels rose dramatically 
and muscular rigidity appeared with the result that the 
clinical picture in this episode was indistinguishable from 
the NMS. 
Patient 1 accidentally received a single doze of clothiapine 
on day 14, during recovery which caused marked extrapyramidal 
signs, but CPKmm levels remained normal and no further signs 
of NMS developed later. She was challenged with clozapine on 
· day 17 to treat psychotic symptoms, with no signs of 
recurrence. 
Patient 2 was challenged during recovery with clozapine on 
hospital day 6 and showed no signs of recurrence. 
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In summary, therefore, two patients (3 and 6) showed an 
intensification of symptoms when neuroleptics were given 
inadvertently in the acute phase of illness. However, three 
patients (1, 2, 3) re-challenged with neuroleptics in the 
recovery phase, showed no signs of recurrence of NMS. 
Despite the limited experience gained in this study, it would 
appear that neuroleptics may be used to treat post-NMS 
psychosis provided they are reintroduced following the 
resolution of the antecedent catatonic state. It is suggested 
that neuroleptics should not be considered until there is a 
marked improvement in clinical status and the CPKmm, serum 
iron and white cell count are within normal limits. 
Neuroleptics Contraindicated in the treatment of Catatonia 
The profound illness in this group of patients appeared to be 
precipitated by neuroleptic administration, which indicates 
the potential hazard of using these agents to treat catatonia. 
Certain writers continue to emphasize the differences between 
catatonia and NMS for the purpose of treatment (Fleishhacker 
et al. (1991)). While it has been accepted that the immediate 
cessation of neuroleptics is imperative in the treatment of 
NMS, neuroleptics are recommended as the treatment of 
catatonia. It is unfortunate that this approach has been 
reinforced by the literature. 
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For example, Rosebush and Stewart (1989), in their discussion 
of NMS, stated that "patients with so-called psychogenic 
catatonia usually improve rather than worsen when given 
neuroleptics". 
Goeke et al. {1991), in their description of a case of lethal 
catatonia complicated by NMS following neuroleptic 
administration, commented "the management of lethal catatonia 
requires the use of antipsychotics or neuroleptic medication, 
while the cornerstone of NMS management is the discontinuation 
of such medication". 
This study highlights the fact that the use of neuroleptics is 
a dangerous procedure in catatonic patients and is 
contraindicated in the treatment of this disorder. 
OUTCOME 
The natural course of the syndrome is towards recovery with 
supportive care and the discontinuation of neuroleptics. A 
fulminating course with fatal outcome is usually associated 
with failure of recogni t ion of the syndrome and continued 
administration of neuroleptics. This was illustrated by three 
cases of fatal hyperthermia described by Kish et al. ( 1990), 
where neuroleptics were not discontinued despite the presence 
of the diagnostic features of NMS. Mann et al. (1986), 
commented in a review of 292 cases of lethal catatonia, that 
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65 (22.3%) fatal episodes were associated with neuroleptic 
exposure. 
The long term outcome regarding a recurrence of NMS in these 
patients is unknown as none of them needed on-going 
neuroleptic therapy, and at the time of writing all patients 
were well at two to four years follow-up. It is interesting to 
note that Pope et al. (1991), in their study of 22 patients 
who had experienced episodes of NMS, found that 11 of the 20 
who resumed neuroleptics after the index episode have had no 
r ecurrences of the syndrome after collectively receiving 16 
years of neuroleptic exposure. 
I f NMS is an intensified form of catatonia, as hypothesized, 
i t is highly probable that should any of the patients develop 
another catatonic episode, features identifiable as the NMS 
would develop following neuroleptic exposure. 
FUTURE RESEARCH 
During the present decade there has been an increasing 
awareness and recognition of ~he entity termed the neuroleptic 
malignant syndrome. Recent studies have provided more 
consistent data and possible risk factors have been suggested 
which may predispose a patient to the NMS. 
I t has been hypothesized from the findings i n this small study 
t hat NMS and catatonia probably share a common pathophysiology 
and that certain cases of the NMS are probably an intensified 
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form of the catatonic state that preceded neuroleptic 
exposure. 
This hypothesis needs investigation at both the clinical and 
iaboratory level to clarify the correct nosological status of 
catatonia and NMS. 
A further area to investigate is the occurrence of biochemical 
findings such as abnormal levels of CPKmm and serum iron in 
other psychiatric disorders in order to determine if these 
abnormalities are specific to catatonic states. 
As regards management, the efficacy of pharmacotherapy and ECT 
in the acute and recovery phase of NMS/catatonia needs further 
evaluation. 
The controversy about MH susceptibility in NMS patients which 
has led to the avoidance of the use of succinylcholine when 
administering a general anaesthetic to NMS patients, needs to 
be resolved by systematic clinical and laboratory study. In a 
laboratory setting this may require the inclusion of a group 
of non-NMS but neuroleptic exposed psychiatric patients, in 
addition to the three groups already studied (NMS patients, MH 
patients, and normal controls). 
Unfortunately, the paucity of patients presenting with 
features of NMS pose problems for future research . Deng et 
al. ( 1990) , commented that "the conundrums of neuroleptic 
malignant syndrome will remain unresolved until a uniform 
protocol for case ascertainment, data collection and treatment 
is prospectively applied at a large number of psychiatric 
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The neuroleptic malignant syndrome has been discussed from the 
perspective of the findings in a small group of patients. The 
outstanding feature in all of these cases was a catatonic 
state of acute onset which preceded neuroleptic administration 
and the emergence of the so-called neuroleptic malignant 
syndrome. 
The similar clinical and laboratory features of NMS and 
catatonia noted in these patients reflect the probable common 
pathophysiology and unitary nature of the disorders. 
Comments in recent literature, "where have all the catatonics 
gone?" (Mahendra, 1981) and "while the use of antipsychotic 
agents has nearly eradicated lethal catatonia, it has led to 
the emergence of the NMS" (Goeke et al. 1991), draw attention 
not only to the disappearance of catatonia, and the probable 
over-reporting of NMS, but highlight the loss of perspective 
concerning these disorders. 
In revising the nosology which presently embraces catatonia 
and NMS as separate disorders, it is necessary to liberate 
scientific reasoning from the restraints imposed by a 
seductive terminology. 
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It is suggested therefore that the term neuroleptic malignant 
syndrome is misleading and no longer serves a useful purpose. 
The broader category of catatonia is preferable as the primary 
diagnosis, which provides the clinician with a wide range of 
options when exploring possible contributory or aetiological 
factors bearing on the catatonic state. 
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